Study finds that early parenteral prostacyclin therapy enables near-normal haemodynamics in severe pulmonary arterial hypertension patients, European Respiratory Journal, July 16, 2026

In a single-centre Japanese cohort of 101 patients with haemodynamically severe pulmonary arterial hypertension treated with parenteral prostacyclin (1999–2023), 22 patients (22%) achieved near-normal haemodynamics and were successfully weaned off prostacyclin, all without adverse events, after a mean of 7.7 years of treatment. Those who de-escalated tended to have started prostacyclin earlier in their disease […]

Study finds that early parenteral prostacyclin therapy enables near-normal haemodynamics in severe pulmonary arterial hypertension patients, European Respiratory Journal, July 16, 2026 Read Post »

Pulmonary endarterectomy vs balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension, BMC Pulmonary Medicine, August 6, 2025

A study recently published on BMC Pulmonary Medicine compared baseline characteristics and short-term efficacy of pulmonary endarterectomy (gold standard for operable chronic thromboembolic pulmonary hypertension, removing thickened intima and organized thrombus from pulmonary arteries) vs. balloon pulmonary angioplasty (an option for inoperable chronic thromboembolic pulmonary hypertension, improving blood flow by dilating stenosed/occluded vessels without removing lesions), particularly

Pulmonary endarterectomy vs balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension, BMC Pulmonary Medicine, August 6, 2025 Read Post »

Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension (CTEPH), Journal of the American College of Cardiologists, June 2025

While pulmonary endarterectomy (PEA) is the primary treatment in chronic thromboembolic pulmonary hypertension (CTEPH), it is not feasible for at least 40% of patients. Balloon pulmonary angioplasty (BPA) has emerged as an alternative for these patients.The International Balloon Pulmonary Angioplasty (BPA) Registry aimed to assess practices and outcomes across 18 centers in the U.S., Europe,

Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension (CTEPH), Journal of the American College of Cardiologists, June 2025 Read Post »

Recent report reveals wide regional variability in access to pulmonary endarterectomy (PEA) and balloon pulmonary angioplasty (BPA) for chronic thromboembolic pulmonary hypertension (CTEPH)

The CLARITY survey, the findings of which were published in the Pulmonary Circulation April 2024 issue (link), aimed to collect data on current chronic thromboembolic pulmonary hypertension (CTEPH) diagnosis, treatment, and management, and to identify unmet medical needs. Conducted from September 2021 to May 2022, the survey targeted hospital-based medical specialists via Scientific Societies and

Recent report reveals wide regional variability in access to pulmonary endarterectomy (PEA) and balloon pulmonary angioplasty (BPA) for chronic thromboembolic pulmonary hypertension (CTEPH) Read Post »

The lay summary of the European Society of Cardiology and European Respiratory Society clinical guidelines on pulmonary hypertension is now available in 11 languages

Did you know that the lay summary of the European Society of Cardiology and European Respiratory Society clinical guidelines on pulmonary hypertension is now available in 11 languages: English, French, German, Greek, Italian, Polish, Portuguese (Portugal), Russian, Spanish, Romanian, Ukrainian. The English version of the lay summary was developed with the active collaboration of the two

The lay summary of the European Society of Cardiology and European Respiratory Society clinical guidelines on pulmonary hypertension is now available in 11 languages Read Post »

TRANSLATE »
Scroll to Top